Gefapixant 45 mg twice daily (BID)

Phase 3

MERCK (MRK)

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No Catalysts Found

No catalyst events have been recorded for this drug yet.

Competitive Landscape

1 competitor in Chronic Cough

GSKcamlipixant

Phase 3

View Full Landscape

Drug Information

Target Indication

Chronic Cough

Clinical Trial

NCT04525885

Last updated: 12/16/2025

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Regulatory Approvals

EMAPending

Gefzuris

Treatment of refractory or unexplained chronic cough.

View on EMA

EMA9/15/2023

Lyfnua

Lyfnua is indicated in adults for the treatment of refractory or unexplained chronic cough.

View on EMA

Drug Science

Mechanism of action & safety profile

Developer

MRK

MERCK

Pharmaceutical Preparations•North America•NASDAQ

Related Pipeline

MK-8748Phase 3

Diabetic Retinopathy

alendronate with cholecalciferolPhase 3

Osteoporosis

Simvastatin 20 mg dailyPhase 3

Cardiovascular Disease

EpinephrinePhase 3

Malignant Neoplasms of Male Genital Organs

9 valent human papillomavirus vaccine (Types 6, 11, 16, 18, 31, 33, 45, 52, 58)Phase 3

HPV Positive Oropharyngeal Squamous Cell Carcinoma

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts